BFRI · Biofrontera Inc. · Documents

Mar 20

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $37.32M ▲ 9.5% Net loss $17.76M Diluted EPS -$3.22

Jan 17

Registration statement S-1

Registration statement

Nov 27

Current report 8-K Events of Nov 21

Entered into a material agreement, New debt or off-balance-sheet obligation, Delisting notice or listing transfer

Nov 22

Current report 8-K

Regulation FD disclosure

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $9.01M ▲ 1.3% Net loss $5.67M Diluted EPS -$0.98

Nov 13

Earnings call

Q3 2024 earnings call

Nov 13

Current report 8-K

Financial results

Oct 31

Current report 8-K

Regulation FD disclosure

Oct 7

Current report 8-K

Regulation FD disclosure

Aug 14

Earnings call

Q2 2024 earnings call

Aug 14

Current report 8-K

Financial results

Aug 14

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $7.84M ▲ 34.0% Net loss $257K Diluted EPS -$0.05

Jun 24

Current report 8-K

Regulation FD disclosure

Jun 14

Current report 8-K Events of Jun 12

Director or officer change, or executive pay, Shareholder vote results

May 22

Current report 8-K Events of May 17

Other events

May 15

Earnings call

Q1 2024 earnings call

May 15

Current report 8-K

Financial results

May 15

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $7.91M ▼ 9.4% Net loss $10.44M Diluted EPS -$2.88

May 3

Current report 8-K Events of May 2

Regulation FD disclosure, Other events

May 3

Registration statement S-1

Registration statement

Apr 30

Current report 8-K Events of Apr 25

Charter or bylaw amendment, or fiscal year change

Apr 30

Proxy statement DEFR14A

Proxy statement

Apr 25

Current report 8-K Events of Apr 24

Shareholder vote results

Apr 17

Proxy statement DEF 14A

Proxy statement

Apr 3

Current report 8-K/A Events of Mar 26

Other events

Mar 26

Current report 8-K

Shareholder director nominations, Other events

Mar 21

Proxy statement DEF 14A

Proxy statement

Mar 20

Registration statement S-1/A

Registration statement

Mar 15

Current report 8-K

Financial results

Mar 15

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $34.07M ▲ 18.8% Net loss $20.13M Diluted EPS -$13.02

Mar 11

Registration statement S-1

Registration statement

Mar 8

Proxy statement PRE 14A

Proxy statement

Feb 23

Current report 8-K Events of Feb 19

Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure, Other events

Feb 20

Current report 8-K Events of Feb 13

Entered into a material agreement, Regulation FD disclosure, Other events

Feb 13

Current report 8-K Events of Feb 9

Other events

Feb 5

Current report 8-K

Regulation FD disclosure

Feb 2

Current report 8-K Events of Jan 29

Entered into a material agreement, Other events

Jan 29

Registration statement S-1/A

Registration statement

Jan 25

Current report 8-K Events of Jan 19

Delisting notice or listing transfer

Jan 17

Registration statement S-1

Registration statement

Jan 11

Earnings call

Q4 2023 earnings call

Jan 11

Current report 8-K

Financial results

Jan 9

Current report 8-K/A Events of Dec 21

Ended a material agreement

Jan 3

Current report 8-K Events of Dec 29

Entered into a material agreement, Regulation FD disclosure

Dec 28

Current report 8-K Events of Dec 21

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation

Dec 27

Current report 8-K Events of Dec 20

Shareholder vote results

Dec 15

Current report 8-K Events of Dec 12

Entered into a material agreement

Nov 29

Current report 8-K Events of Nov 22

Delisting notice or listing transfer

Nov 17

Proxy statement DEF 14A

Proxy statement

Nov 9

Earnings call

Q3 2023 earnings call